The Pharmaceutical Journal
Vol 280 No 7498 p461
19 April 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Singulair and suicidal behaviour

A possible association between the use of montelukast (Singulair) and suicidal thinking and behaviour is being investigated by the US Food and Drug Administration.

Over the past year (2007), manufacturer Merck & Co has updated US prescribing information to include advice on tremor, depression, suicidal thinking and behaviour and anxiousness. The FDA has asked Merck to evaluate study data for more information on suicidal thinking and behaviour but expects the evaluations to take up to nine months.